Involvement of lysosomal labilisation and lysosomal/mitochondrial cross-talk in diclofenac induced hepatotoxicity

Iranian Journal of Pharmaceutical Research

Volumn 10, Issue 4, 2011, Pages 877-887

  Pourahmad, Jalal ^a   Mortada, Yassar ^a   Eskandari, Mohammad Reza ^b   Shahraki, Jafar ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytochrome P450; Cytotoxicity; Diclofenac; Lysosome; Mitochondria

Indexed keywords

4 METHYLPYRAZOLE; ALPHA TOCOPHEROL SUCCINATE; CARNITINE; CASPASE 3; CHLOROQUINE; CYCLOSPORIN; CYTOCHROME C; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 ISOENZYME; DEFEROXAMINE; DICLOFENAC; DIMETHYL SULFOXIDE; DIPHENYLIODONIUM SALT; GLUTATHIONE; MANNITOL; METHYLAMINE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; REACTIVE OXYGEN METABOLITE; SULFAPHENAZOLE; TRIFLUOPERAZINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENDOCYTOSIS; ENZYME ACTIVATION; LIPID PEROXIDATION; LIVER CELL DAMAGE; LIVER LYSOSOME; LIVER MITOCHONDRION; LIVER TOXICITY; MALE; MEMBRANE RUPTURE; MOLECULAR INTERACTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; RAT; TOXICOKINETICS;

EID: 84858607503     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Gómez-Lechón MJ, Ponsoda X, O>Connor E, Donato T, Jover R and Castell JV. Diclofenac induces apoptosis in hepatocytes. Toxicol. In-vitro. (2003) 17: 675-680.
2. Iveson TJ, Ryley NG, Kelly PM, Trowell JM, McGee JO and Chapman RW. Diclofenac associated hepatitis. J. Hepatol. (1990) 10: 85-89.
3. Galati G, Tafazoli S, Sabzevari O, Chan TS and O>Brien PJ. Idiosyncratic NSAID drug induced oxidative stress. Chem. Biol. Interact, (2002) 142: 25-41.
4. Pourahmad J. The Need to Establish a Common Base Line for the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets. Iranian J. Pharm. Res. (2008) 7: 233-235.
5. Purcell P, Henry D and Melville G. Diclofenac hepatitis. Gut. (1991) 32(11): 1381-1385.
6. Suzuki H, Inoue T, Matsushita T, Kobayashi K, Horii I, Hirabayashi Y and Inoue T. In-vitro gene expression analysis of hepatotoxic drugs in rat primary hepatocytes. J. Appl. Toxicol. (2008) 28: 227-236.
7. Schmitz G, Stauffert I, Sippel H, Lepper H and Estler CJ. Toxicity of diclofenac to isolated hepatocytes. J. Hepatol. (1992) 14: 408-409.
8. Jurima-Romet M, Crawford K and Huang HS. Comparative cytotoxicity of non-steroidal anti-inflammatory drugs in primary cultures of rat hepatocytes. Toxicol. In-vitro. (1994) 8: 55-66.
9. Bort R, Ponsoda X, Jover R, Gómez-Lechón MJ and Castell JV. Diclofenac Toxicity to Hepatocytes: A Role for Drug Metabolism in Cell Toxicity. J. Pharmacol. Exp. Ther. (1998) 288: 65-72.
10. Pumford NR, Myers TG, Davila JC, Highet RJ and Pohl LR. Immunochemical detection of liver protein adducts of the non-steroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol. (1993) 6: 147-150.
11. Hargus SJ, Martin BM, George JW and Pohl LR. Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the non-steroidal anti-inflammatory drug diclofenac. Chem. Res. Toxicol. (1995) 8: 993-996.
12. Kretz-Rommel A and Boelsterli UA. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol. (1993) 120: 155-161.
13. Boelsterli UA, Zimmerman HJ and Kretz-Rommel A. Idiosyncratic liver toxicity of non-steroidal antiinflammatory drugs: Molecular mechanisms and pathology. Crit. Rev. Toxicol. (1995) 25: 207-235.
14. Gil ML, Ramirez MC, Terencio MC and Castell JV. Immunochemical detection of protein adducts in cultured human hepatocytes exposed to diclofenac. Biochem. Biophys. Acta. (1995) 1272: 140-146.
15. Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP, Dean DC, Pang J, Leung KH, Doss GA, Strauss JR, Kwei GY, Rushmore TH, Chiu SH and Baillie TA. Studies on cytochrome P450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug. Metab. Dispos. (1999) 27: 365-372.
16. Miyamoto G, Zahid N and Uetrecht JP. Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase and hypochlorous acid. Chem. Res. Toxicol. (1997) 10: 414-419.
17. Stierlin H and Faigle JW. Biotransformation of diclofenac sodium (Voltaren) in animals and man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. Xenobiotica. (1979) 9: 611-621.
18. Shen S, Marchick MR, Davis MR, Doss GA and Pohl LR. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol. (1999) 12: 214-222.
19. Chan K, Jensen N and O'Brien PJ. Structure-activity relationships for thiol reactivity and rat or human hepatocyte toxicity induced by substituted p-benzoquinone compounds. J. Appl Toxicol. (2008) 28: 608-620.
20. Galati G, Teng S, Moridani MY, Chan TS and O>Brien PJ. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug. Metabol. Drug. Interact. (2000) 17: 311-349.
21. Pourahmad J. Identification of Intracellular Sources Responsible for Endogenous Reactive Oxygen Species Formation. IJPR. (2002) 1: 21-29.
22. Jamshidzadeh A, Niknahad H and Kashafi H. Cytotoxicity of chloroquine in isolated rat hepatocytes. J. Appl. Toxicol. (2007) 27: 322-326.
23. Hissin J and Hilf R. A fluorometric method for determination of oxidised and reduced glutathion in tissues. Anal. Biochem. (1976) 74: 214-226.
24. Andersson BS, Aw TY and Jones DP. Mitochondrial transmembrane potential and pH gradient during anoxia. Am. J. Physiol. (1987) 252: C349-355.
25. Pourahmad J, Amirmostofian M, Kobarfard F and Shahraki J. Biological reactive intermediates that mediate dacarbazine cytotoxicity. Cancer. Chemother. Pharmacol. (2009) 65: 89-96.
26. Novak RF, Kharasch ED and Wendel NK. Nitrofurantoin stimulated proteolysis in human erythrocytes: a novel index of toxic insult by nitroaromatics. J. Pharmacol. Exp. Ther. (1988) 247: 439-444.
27. Sakahira H, Enari M and Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. (1998) 391: 96-99.
28. Lim MS, Lim PL, Gupta R and Boelsterli UA. Critical role of free cytosolic calcium, but not uncoupling, in mitochondrial permeability transition and cell death induced by diclofenac oxidative metabolites in immortalized human hepatocytes. Toxicol. Appl. Pharmacol. (2006) 217: 322-331.
29. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. (2003) 192: 307-322.
30. Tuschl G, Lauer B and Mueller SO. Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. Expert. Opin. Drug. Metab. Toxicol. (2008) 4: 855-870.
31. Tugwood JD and Montague CT. Biology and toxicology of PPARgamma ligands. Hum. Exp Toxicol. (2002) 21: 429-437.
32. He K, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges AJ and Woolf TF. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug. Metab. Dispos. (2004) 32: 639-646.
33. Pompella A, Visvikis A, Paolicchi A, De Tata V and Casini AF. The changing faces of glutathione, a cellular protagonist. Biochem. Pharmacol. (2003) 66: 1499-1503.
34. Rezaei M, Rasekh HR, Ahmadiani A and Pourahmad J. Involvement of subcellular organelles in inflammatory pain-induced oxidative stress and apoptosis in the rat hepatocytes. Arch. Iran. Med. (2008) 11: 407-417.
35. Banos G and Reyes PA. A comparative study of the effect of ten non-steroidal anti inflammatory drugs (NSAIDs) upon some mitochondrial and platelet functions. Int. J. Biochem. (1989) 21: 1387-1394.
36. Uyemura SA, Santos AC, Mingatto FE, Jordani MC and Curti C. Diclofenac sodium and mefenamic acid: Potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch. Biochem. Biophys. (1997) 342: 231-235.
37. Masubuchi Y, Nakayama S and Horie T. Role of Mitochondrial Permeability Transition in Diclofenac-Induced Hepatocyte Injury in Rats. Hepatology. (2002) 35: 544-551.
38. Boelsterli U and Priscilla L. Mitochondrial abnormalities: A link to idiosyncratic drug hepatotoxicity. Toxicol. Appl. Pharmacol. (2007) 220: 92-107.
39. Kowaltowski AJ, Castilho RF and Vercesi AE. Opening of the mitochondrial permeability transition pore by uncoupling or inorganic phosphate in the presence of Ca2+ is independent of mitochondrial generated reactive oxygen species. FEBS. Lett. (1996) 378: 150-152.
40. Pourahmad J and O'Brien PJ. A comparison of hepatocyte cytotoxic mechanisms for Cu2+and Cd2+. Toxicology. (2000) 143: 263-273.
41. Boelsterli UA. Xenobiotict-induced oxidative stress: Cell injury, signaling, and gene regulation. In: Boelsterli UA, editor. Mechanistic Toxicology: The Molecular Basis of How Chemicals Disrupt Biological Targets, 2nd ed. Boca Raton, FL: CRC Press. (2007) 117-175.
42. Bove Boveris A, Fraga CG, Varsavsky AI and Koch OR. Increased chemiluminescence and superoxide production in the liver of chronically ethanol-treated rats. Arch. Biochem. Biophys. (1983) 227: 534-541.
43. Ekström G and Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem. Pharmacol. (1989) 38: 1313-1319.
44. Rashba-Step J, Turro NJ and Cederbaum AI. Increased NADPH and NADH-dependent production of superoxide and hydroxyl radical by microsomes after chronic ethanol treatment. Arch. Biochem. Biophys. (1993) 300: 401-408.